**ANRIL promoter DNA methylation: a perinatal marker for later adiposity**

Karen Lillycrop1,2\*, Robert Murray3\*, Clara Cheong4, Ai Ling Teh4, Rebecca Clarke-Harris3, Sheila Barton5, Paula Costello3, Emma Garratt2,3, Eloise Cook3, Philip Titcombe5, Bhuvaneshwari Shunmuganathan4, Samantha J Liew4, Yong-Cai Chua4, Xinyi Lin4, Yonghui Wu4, Graham C. Burdge3, Cyrus Cooper5, Hazel M. Inskip3,5, Neerja Karnani4, James C. Hopkins6, Caroline E. Childs3,5, Carolina Paras Chavez3, Philip C. Calder2,3,7, Fabian Yap8,9,10, Yung Seng Lee4,11, Yap Seng Chong4,12, Philip E. Melton13,14, Lawrie Beilin15, Rae-Chi Huang16, Peter D. Gluckman17, Nick Harvey3,5, Mark A. Hanson2,3, Joanna D. Holbrook4, the EpiGen Consortium, Keith M. Godfrey2,3,5+

\*Joint first authors. +Corresponding author. 1Centre for Biological Sciences, Faculty of Natural and Environmental Sciences, University of Southampton, Southampton, UK, 2NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK, 3Academic Unit of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK, 4Singapore Institute for Clinical Sciences (SICS), Agency for Science Technology and Research (A\*STAR), Singapore, 5MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK, 6Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK, 7Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia, 8 Department of Paediatrics, KK Women’s and Children’s Hospital, Singapore, 9 Duke NUS Graduate School of Medicine, Singapore, 10Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, 11Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 12Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 13Centre for Genetics of Health and Disease, University of Western Australia, 14Faculty of Health Science, Curtin University 15School of Medicine and Pharmacology, University of Western Australia, 16Telethon Kids Institute, University of Western Australia, Perth, Australia, 17Liggins Institute, University of Auckland, Auckland, New Zealand.

**Abstract**

Experimental studies show a substantial contribution of early life environment to obesity risk through epigenetic processes. We examined inter-individual DNA methylation differences in human birth tissues associated with child’s adiposity. We identified a novel association between the level of CpG methylation at birth within the promoter of the long non-coding RNA ANRIL (encoded at *CDKN2A*) and childhood adiposity at age 6-years. An association between ANRIL methylation and adiposity was also observed in three additional populations; in birth tissues from ethnically diverse neonates, in peripheral blood from adolescents, and in adipose tissue from adults. Additionally, CpG methylation was associated with ANRIL expression *in vivo*, and CpG mutagenesis *in vitro* inhibited ANRIL promoter activity. Furthermore, CpG methylation enhanced binding to an Estrogen Response Element within the ANRIL promoter. Our findings demonstrate that perinatal methylation at loci relevant to gene function may be a robust marker of later adiposity, providing substantial support for epigenetic processes in mediating long-term consequences of early life environment on human health.

**Keywords**:

DNA methylation

Adiposity

epigenetic

**Highlights**

* DNA methylation within the ANRIL promoter region was predictive of measures of adiposity in four independent cohorts
* DNA methylation may be a marker for late gestation fetal undernutrition, followed by rapid postnatal weight gain
* Altered DNA methylation associated with p16INK4a and p14ARF expression.
* ERα may bind at the ANRIL promoter, and *in vitro* E2 treatment stimulated expression of ANRIL, while reducing p14 expression

**Research in context**

The quality of the early life environment before birth can affect susceptibility to metabolic disease later in the lifecourse, with epigenetic regulation of gene function thought to be one mechanism through which early life environmental factors induce persistent phenotypic changes. In this study, using DNA from the Southampton Women’s Survey (SWS), we identified changes in DNA methylation levels at birth that associated with adiposity later in childhood within the promoter of ANRIL, a gene with strong disease associations that is involved in regulatiing cellular growth. This finding was replicated in several independent cohorts, and functionally validated in adipocyte cells.

**Introduction**

Fixed variations in a number of genes have been linked to obesity1-3, although to date single nucleotide polymorphisms and copy number variations explain only a fraction of the risk of obesity and metabolic disease in humans4. However, there is now substantial evidence from both human and animal studies that the quality of the early life environment before and after birth can affect susceptibility to metabolic disease in later life5. In humans, famine exposure during pregnancy6, maternal obesity7,8, and gestational diabetes9 are all associated with an increased risk of obesity in the offspring, while in animal studies variation in maternal diet has been linked to alterations in offspring metabolism and body composition10,11.

Epigenetic regulation of gene function is one mechanism through which early life environmental factors could induce persistent phenotypic changes. For example, feeding rats a modest reduction in protein during pregnancy induced hypomethylation of the promoter regions of the nuclear receptors Glucocorticoid Receptor (*NR3C1*) and Peroxisome Proliferator activated receptor alpha (*PPARA*) in the liver of the offspring during adulthood, accompanied by increased *NR3C1* and *PPARA*gene expression, and alterations in the metabolic processes they control12. In humans, differences in the methylation of imprinted and non-imprinted genes related to cardio-metabolic phenotypes have been found in the peripheral blood leukocytes of adults whose mothers were exposed to famine during pregnancy13. Consistent with the paradigm that developmentally induced epigenetic marks make a significant contribution to later phenotype, DNA methylation within the promoter of the retinoid X receptor alpha (*RXRA*) gene in umbilical cords predicted >25% of the variation in later %fat mass in children14, while PPAR-γ-co-activator-1α promoter methylation in blood at age 5–7 years predicted adiposity from 9 to 14 years15. As the identification of such epigenetic changes may provide insights into the molecular mechanisms underlying the development of adiposity and allow the identification of individuals at increased risk of metabolic disease, we carried out a discovery genome-scale DNA methylation scan to identify differences in DNA methylation levels in umbilical cord from children from the Southampton Women’s Survey (SWS) cohort associated with child’s adiposity at age 6 years. We identified an association between the methylation level at birth of CpG loci within the promoter of ANRIL (antisense non-coding RNA in the *INK4* locus), a 3.8Kb non-coding RNA transcribed from the *CDKN2A* gene locus, and variation in total and %fat mass at 6 years. We also observed this association in cord tissue from ethnically diverse neonates from the Growing Up in Singapore with Healthy Outcomes (GUSTO) cohort (n=187), in peripheral blood from adolescents (n=812) in the Western Australian Pregnancy (RAINE) cohort, and in adipose tissue from adults (n=81) from the UK BIOCLAIMS cohort. Finally, we showed that CpG methylation at this locus was associated with ANRIL expression *in vivo* andCpG mutagenesis *in vitro* inhibited ANRIL promoter activity. Furthermore, we identified an Estrogen Receptor-α (ERα) containing protein complex that binds to this region in a methylation specific manner and regulates transcription from this locus.

**Results**

**Differentially Methylated Regions (DMRs) at birth are associated with later adiposity**

To identify perinatal epigenetic biomarkers associated with later adiposity, we carried out a discovery scan of DNA methylation in the promoters of all refseq genes in umbilical cord DNA, comparing locus specific DNA methylation levels at birth with differences in percentage (%) fat mass in the children aged 6 years (Figure 1A; Table S2). Methylated DNA was captured using the methyl-binding domain (MBD) of MBD2, before the enriched methylated DNA fraction and input DNA was hybridised to the Agilent Human Promoter Whole-Genome array (G4489A). DNA methylation levels were estimated, adjusting for CpG density, using the validated algorithm BATMAN16. This identified 93 differentially methylated regions (DMRs) associated with %fat mass in the children at 6 years of age measured by dual-energy X-ray absorptiometry (DXA)(Table S3). The top pathway enriched amongst the 93 DMRs was DNA replication and repair (P=1 x10-41), (Figure 1B, Table S4); 41 of the 93 DMRs were associated with this pathway. The DNA replication and repair pathway included DMRs linked with Cyclin dependent Kinase 2A inhibitor (*CDKN2A*), cyclin D (*CCND1*), flap structure-specific endonuclease 1 (*FEN1*), proliferating cell nuclear antigen (*PCNA*) and A-kinase anchor protein 8 (*AKAP8*) (Figure 1B). Cell cycle regulators have been increasingly linked to the control of metabolism. The cell cycle inhibitors p16INK4a (inhibitor of cyclin-dependent kinase 4) and P14ARF (alternative reading frame relative to p16), encoded by the CDKN2A locus, have been shown to play a direct role in regulating adipocyte number, function and senescence17. Furthermore multiple GWAS studies have identified the CDKN2A locus, particularly the region encoding the long non-coding RNA ANRIL which negatively regulates p16INK4A, as a hotspot for cardiovascular disease, type 2 diabetes, and frailty. However to date there have been no studies linking the differential methylation of *CDKN2A* or ANRIL with adiposity. We therefore further explored the association between the differentially methylated region within the CDKN2A locus at birth and child’s %fat mass.

**Lower *CDKN2A* methylation is associated with increased child adiposity**

Analysis of the promoter array revealed an association between lower methylation of the *CDKN2A* DMR at birth and higher %fat mass age 6-years (Figure 2A-B). The association remained after array-wide adjustment for surrogate variables18 (a procedure similar to that of Houseman *et al.,*19), suggesting that cellular heterogeneity did not confound the association (Table S5). To validate the relationship between *CDKN2A* methylation and %fat mass age 6-years, sodium bisulfite pyrosequencing was carried out across the *CDKN2A* DMR in an independent group of infants from the SWS cohort (n=247). The correlation between observed DNA methylation values at the 9 CpG dinucleotides was examined: two clusters of contiguous CpGs with highly correlated methylation levels (spearman rho > 0.68) could be determined within the *CDKN2A* DMR, CpGs 1-2 and CpGs 4-8, (Figure 3A), Within these two clusters the CpGs with the highest median absolute deviation (MAD) score, CpG 2 and CpG 7, were selected as the representative CpG for those clusters in further analysis (Figure 3C). As CpGs 3 and 9 showed some divergence from their neighbours they were tested individually.

Lower DNA methylation was associated with higher %fat mass age 6-years for CpG clusters 1-2 (p=0.003), 3 (p=0.007), and 4-8 (p=0.042), but not CpG9 (p=0.122). Lower DNA methylation was also associated with higher %fat mass age 4-years for cluster 1-2 (p=0.007) and cluster 4-8 (p=0.040) (Table 1). Data for the individual CpGs is also given in Table S6. For every 10% increase in perinatal *CDKN2A* CpG1 methylation there was a decrease in %fat mass of 0.20 SD (95% CI -0.33, -0.06) age 4 years and 0.18 SD (-0.31, -0.05) age 6 years, controlling for sex. Methylation of all four clusters was also associated with total fat mass ages 4 and 6-years (all p≤0.03)(Table 1). We observed no associations between *CDKN2A* methylation and DXA %fat mass or total fat mass at birth (data not shown).

Genotyping was carried out for all known SNPs within the DMR region to investigate whether genetic variation explained the observed association between methylation levels and adiposity. Of the five SNPs analysed, three SNPs (rs192633385, rs190416574, rs187674321) were monomorphic in this population, while SNPs rs149570278 and rs111690342 were heterozygous with frequencies of 1.4% and 1.7% respectively; analysis showed no impact on the association between methylation and adiposity (data not shown).

***CDKN2A* methylation is associated with triceps skinfold thickness in early infancy**

*CDKN2A* methylation was associated with DXA measures of adiposity at 4 and 6 years of age, but not at birth; to examine this temporal difference in associations, we related perinatal *CDKN2A* methylation to triceps skinfold thickness, measured immediately after birth and at age 1-year. There was no association between DMR methylation and triceps skinfold thickness at birth, but an inverse association between methylation of CpG clusters 1-2, 3 and 4-8 with triceps skinfold thickness at age 1-year (p=0.039, p=0.068 and p=0.014 respectively)(Table 2A). As one pathway to obesity has been suggested to involve fetal undernutrition followed by rapid postnatal weight gain, we used longitudinal measurements of fetal growth from the SWS cohort to derive conditional abdominal growth velocity in late gestation and related this to cord *CDKN2A* methylation. Here we found that fetal growth faltering between week 34 of gestation and birth was associated with lower *CDKN2A* methylation (Figure S1, Table S1).

***CDKN2A* methylation in Singaporean infants is associated with adiposity**

We examined DNA methylation of the 4 CpG clusters in umbilical cord DNA from the GUSTO cohort (n=305), an independent Singaporean mother-offspring cohort where triceps and subscapular skinfold thickness had been measured at age 7-days and ponderal index age 18-months (Table 2B and Table S8). Analysis of GUSTO methylation levels at the nine CpGs showed a similar pattern of relatedness amongst CpGs (Figure 3B). There was an even more divergent methylation profile at CpG9, suggesting the four test variables consisting of the two CpGs representative of larger contiguous correlated clusters and the two individual CpGs were appropriate across cohorts (Figure S1C). Lower methylation of *CDKN2A* CpG cluster 3 (p=0.004), was associated with greater triceps skinfold thickness at age 7-days (Table 2B), while associations or trends were also seen between lower methylation of CpG 3 (p=0.004), and 9 (p=0.08) and higher subscapular skinfold thickness at age 7 days, and between lower methylation of CpG 9 (p=0.005) and greater ponderal index at age 18 months (Table S8), after adjustment for sex, maternal age, ethnicity, mode of delivery and cell type.

***CDKN2A* methylation is associated with the expression of p16INK4a, P14ARF and ANRIL expression in umbilical cord**

As the *CDKN2A* gene locus encodes for the cell cycle inhibitors p14ARF and p16INK4a, as well as ANRIL, a long non-coding RNA, we investigated whether the methylation status of the CpG loci within the *CDKN2A* DMR was associated with the expression of transcripts generated from this gene locus in umbilical cord samples from the GUSTO cohort, for which both DNA and RNA was available. Expression of the unspliced form of the long non-coding RNA ANRIL was positively associated with the methylation of CpG cluster 9 (p=0.02), while the spliced linear form of ANRIL was positively associated with the methylation of CpG cluster 4-8 (p=0.02) (Table 3). There was no association between expression of the circular form of ANRIL and methylation of the DMR CpG clusters. In contrast, there was an inverse association between methylation of CpG cluster 9 and both p16INK4a and p14ARF expression (both p=0.01).

As the methylation of CpGs within the DMR of *CDKN2A* DMR was associated with expression of ANRIL, p16INK4a and p14ARF transcripts, we also examined whether the expression of these transcripts was associated with infant adiposity (Table S9). The expression of the circular and unspliced forms of ANRIL were positively associated with triceps (p=0.02 and p=0.01) and subscapular skinfold (p=0.05 and p=0.01) thickness at day 7 (D7) in GUSTO infants. In contrast, there was a negative association between p14ARF expression and day 7 ponderal index measurements (p=0.04), while expression of p16INK4 was positively associatedwith both triceps (p=0.04) and subscapular (p=0.02) skinfold thickness at 18 months.

***CDKN2A* methylation in whole blood DNA is associated with BMI**

Having observed an association between *CDKN2A* DMR methylation at birth with measures of adiposity in infancy and childhood, we next investigated whether *CDKN2A* methylation was associated with adiposity at an older age. DMR CpG methylation was measured in peripheral blood samples from adolescents aged 17-years from the Western Australian RAINE mother-offspring cohort (n=814), examining the correlation between *CDKN2A* methylation in peripheral blood and adiposity. Analysis of the 9 CpGs showed CpG clusters with highly correlated methylation levels (Figure S1D) similar to those observed in SWS and GUSTO. Adjusting for age and sex, lower methylation of CpG clusters 4-8 and 9 was associated with higher BMI (p=0.008 and p=0.006), with a trend observed between CpG3 and BMI (p=0.06) (Table 4). Blood cell counts were measured in these samples but due to an observed strong collinearity (Table S11A and B) between blood cell counts and BMI (Variance Inflation Factors were extremely high (25 to 113.7) (Table S11C) increasing the variance of the regression coefficients and making them unstable), it was not therefore possible to adjust the association between methylation and BMI for cell type.

***CDKN2A* methylation is reduced in adipose tissue of obese adults**

Having found an association between *CDKN2A* methylation in DNA from peripheral tissues and measures of adiposity, we next investigated whether these same CpG loci were differentially methylated in subcutaneous adipose tissue of obese compared to lean adults from the BIOCLAIMS cohort(http://bioclaims.uib.eu) (Table S11). %fat mass was used to characterize subjects as lean (12.2-20.9% for males and 17.3-31.5% for females) or obese (26.8-38% for males, 36.8-52% for females). Controlling for sex and age, methylation of CpG 3 was lower in adipose tissue from obese individuals compared to lean individuals (p=0.04), with a trend also being observed for the methylation CpG9 (p=0.078) (Figure 4A). CpG Clustering based upon correlation of methylation was similar to previously observed (Figure S1E)

**CpG sites within *CDKN2A* regulate ANRIL and p14ARF promoter activity**

As the identified DMR is in close proximity to the transcriptional start site of ANRIL and within the first exon of p14ARF, we investigated whether the DMR CpG sites may play a role in directly regulating the expression of ANRIL and/or p14ARF. The promoter region of ANRIL (-1281bp to +20bp relative to TSS) and the 5’ portion of the p14ARF gene (-500bp to +1125bp relative to TSS) were fused to the reporter gene Luciferase in the vector pGL3basic, and CpG sites 2,3,7 and 9 individually mutated (CpG>TpG) then transfected into the liposarcoma cell line SW-872. Mutation of each of the 4 CpG sites decreased ANRIL promoter activity (all p≤0.008)(Figure 4B). In contrast, only mutation of CpGs 3 and 7 within the context of p14ARF caused a decrease in expression, while alteration of CpGs 2 and 9 had no impact on expression.

**DNA methylation alters protein complex binding within the DMR**

Having shown that CpG loci associated with adiposity can influence the level of ANRIL and p14ARF promoter activity, we used electrophoretic mobility shift assays (EMSAs) to determine whether methylation affected transcription factor binding to this region. The region containing the CpGs of interest was sub-divided into four regions based upon CpG chromosomal position. Incubation of nuclear extracts from SW-872 liposarcoma cells with oligonucleotides covering CpG1, CpGs 2-3, CpGs 4-7 and CpGs 8-9 revealed protein binding to each of the four regions, with binding to the oligonucleotides CpGs 2-3 and CpGs 4-7 competed out by an excess of unlabeled specific competitor (Figure 4C). To determine whether methylation at the CpG 2-3 site affected binding to this sequence, an oligonucleotide containing CpGs 2-3 was incubated with nuclear extracts from liposarcoma cells with 50, 100 and 500-fold excess of either the unmethylated or methylated specific competitor containing a methylated cytosine at CpG2. While binding to the probe was markedly reduced in the presence of a 500-fold excess of the unmethylated specific competitor, only a 50-fold excess of the methylated specific competitor was required to effectively compete out binding (Figure 4D), suggesting that methylation at CpG2 enhances DNA-protein binding. This marked increase in affinity of the protein complex for the methylated sequence was also observed when radiolabelled methylated probe was incubated with increasing concentrations of the unmethylated or methylated competitors (Figure 4E).

**The CpG 2 -3 region contains an Estrogen Response Element**

To identify the complex binding across CpGs 2-3, multiplexed competitor EMSAs were carried out. Multiplexed oligonucleotide DNA consensus sequences for eighty common transcription factors20 were used as competitors against the CpG 2-3 probe to identify potential transcription factors that may bind within the region. The protein complex bound across CpGs 2-3 was effectively competed out by the ERα consensus binding sequence. Consistent with this, addition of the CpG 2-3 unlabelled competitor successfully competed out binding to radiolabelled ERα probe (Figure 4F). DNA sequence analysis of this region revealed the core consensus sequence (GGGTCACCCTCTCCC) for an ERα Estrogen Response Element (ERE) immediately downstream of the CpG 2-3 region matching known ERE conformations21,22, and an upstream AT rich sequence, known to be important for ERα binding23 (Figure 4G). To examine if estrogen can effect ANRIL expression, SW872 cells were treated with 10nM β-Estradiol (E2) for 72hrs. E2 treatment induced a 4-fold increase in expression of unspliced ANRIL (p=0.008). Estrogen treatment decreased p14ARF expression by 2 fold (Figure 4H).

**Discussion**

Differential methylation of specific CpG loci within the promoter region of ANRIL at the *CDKN2A* gene locus was predictive of measures of adiposity in four independent cohorts. In the UK SWS cohort (n=247), umbilical cord *CDKN2A* methylation was negatively associated with %fat mass at ages 4 and 6-years, in the Singapore GUSTO cohort (n=305), it was negatively associated with skinfold thickness or ponderal index at ages 7 days and 18 months, in the Australian RAINE cohort (n=814), whole blood *CDKN2A* methylation was negatively associated with concurrent BMI in 17 year olds and in the UK BIOCLAIMS cohort (n=81) obese individuals had lower adipose tissue *CDKN2A* methylation compared to lean individuals. Although the negative association between *CDKN2A* methylation and adiposity measures was observed across the 4 cohorts, in 3 tissues and 3 age groups, there were differences in the nature of the relations. In the SWS cohort, lower umbilical cord *CDKN2A* DMR methylation predicted increased adiposity at ages 1, 4 and 6 years but not at birth, suggesting that *CDKN2A* methylation may be linked to the gain of fat mass postnatally. Two developmental pathways to obesity have been suggested, one associated with fetal undernutrition, followed by rapid postnatal weight gain, while the second pathway is linked to fetal overnutrition and greater fat mass at birth24,25. Interestingly, fetal growth faltering in late gestation was associated with lower *CDKN2A* methylation at birth, suggesting that *CDKN2A* methylation may be a marker for the former pathway. In the GUSTO cohort, there were associations between the methylation of *CDKN2A* with measures of adiposity from 7 days after birth. The timing of the associations between the cohorts may reflect differences in fat deposition or rate of body fat accumulation between birth and early infancy, potentially due to genetic and epigenetic ancestral differences between the different cohorts that can affect timing of associations.

The associations between the methylation of the individual CpGs within the *CDKN2A* DMR and adiposity were also not identical across the cohorts. The methylation status of CpG sites is often closely aligned to that of their neighbors, however developmentally induced changes are often CpG site specific26. In the DMR examined, the CpGs were divided into distinct groupings based upon strong inter-correlation, but these groupings had distinct differences between them, suggestive of tissue or population differences. This is re-iterated by the EMSAs, which showed that different protein complexes bind across the CpG sites within the DMR, suggesting they are likely to be differentially regulated. This is also supported by the *in vitro* studies, which showed that mutagenesis of the individual CpG sites had differential quantitative effects on expression.

An inverse association between *CDKN2A* methylation in umbilical cord and measures of adiposity was observed in the SWS and GUSTO cohorts. Surrogate variable analysis to control for cellular heterogeneity in cord tissue had little effect on our findings suggesting that, in cord, differences in *CDKN2A* methylation are not dependent upon variation in cellular heterogeneity. An inverse association between *CDKN2A* methylation and obesity was found in adipose tissue from adults, suggesting that differential *CDKN2A* methylation may be a robust marker of adiposity across cord and adipose tissue. The negative association between *CDKN2A* methylation and BMI was again observed in peripheral blood samples from the RAINE cohort. Blood is a heterogeneous material with dynamic cellular proportions and DNA methylation is differential across cell types, making it challenging to resolve the causal relationships between methylation of whole tissue, cellular mix and phenotype. Cellular proportions were measured in the RAINE cohort, however in this (Table S11A) and other studies, cellular proportions strongly associate with BMI. As would be expected methylation levels also differ across cell types (Table S11B). Multicollinearity was seen between all cell types and log BMI for all CpG clusters within the *CDKN2A* DMR. Therefore adjustment of the association between methylation and BMI for cellular proportions would violate the assumption of non-collinearity implicit in regression analysis. Consequently, we were unable to assess the dependence on cellular heterogeneity of the association of *CDKN2A* methylation in blood and BMI, and therefore cannot exclude differences in cellular composition as the explanation for the association between *CDKN2A* methylation in peripheral blood and adiposity in late adolescence. However; the existence of this association in very different tissues, which are (in the case of adipose) more homogenous in their cellular composition, and the fact that in umbilical cord it survived adjustment for cellular heterogeneity, suggests that the relationship is not completely explained by the confounding influence of cell type.

The *CDKN2A* gene locus encodes for p14ARF, p16INK4a, and the long non-coding RNA *ANRIL,* which negatively regulates p16INK4a. p16INK4a inhibits CDK4 and CDK6 activity, which regulate the RB-E2F axis and cell cycle progression27-29,17, while p14ARF also induces cell cycle arrest through its interaction with MDM2, resulting in increased p53 levels that trigger cell cycle arrest at both G1 and G2/M phases30,31. Both p16INK4a and p14ARF also play roles in driving cellular senescence and ageing32,33. There is also evidence that the p16INK4a-cdk4-pRB axis plays a direct role in metabolic regulation and adipocyte differentiation34. Recent studies of genetically engineered mice deficient in E2F1, cdk4, and pRB, have shown that they contribute to lipid synthesis, glucose production, insulin secretion, and glycolytic metabolism. For example, adipose tissue-specific inactivation of the retinoblastoma protein induced increased mitochondrial activity, resulting in increased energy expenditure, which protected from diet-induced obesity35. In addition, inactivation of cdk4, which controls the clonal expansion phase of adipogenesis and phosphorylates PPARγ, blocked adipocyte differentiation, while a Cdk4 mutant, which cannot be inhibited by p16INK4a, increased the adipogenic potential of 3T3-L1 cells17.

Data from the BLUEPRINT epigenome project suggests that the *CDKN2A* DMR overlaps with regulatory sequences. In monocytes, the DMR lies within a DNase hypersensitive peak and is associated with H3K27me3, H3K4me1 and H3K4me3 marks. The existence of both repressive and activating histone marks suggests that a bivalent domain is located across the region, while in B cells and HUVECs, there is a peak of H3Kme1, a mark often enriched at enhancers or regulatory sequences. Consistent with sequences within the DMR having a functional role in the regulation of *CDKN2A* directed transcription, in the GUSTO cohort, where both DNA and RNA were available from the cord tissue, there were associations between the methylation of CpG cluster 4-8 and CpG 9 and the expression of the *CDKN2A* generated transcripts, suggesting that differential CpG methylation within the promoter of ANRIL may have downstream effects on p16INK4a and p14ARF expression. Here, lower CpG methylation was associated with a decrease in ANRIL expression and an increase in p16INK4A and P14ARF expression. Increases in p16INK4a and p14ARF expression would be expected to lead to a decrease in cell proliferation and increased cellular senescence; if re-capitulated in adipocytes, this could promote both a decrease in adipocyte number and impaired adipocyte function, since p16INK4a regulates cdk4 activity, which in turn phosphorylates and activates the adipogenic transcription factor PPARγ. Interestingly the region encoding ANRIL has been identified by GWAS as a hot spot for genetic variation associated with a number of ageing associated diseases, such as CVD and T2D. Sequence alterations within ANRIL may similarly affect p16INK4a expression with downstream effects on cellular senescence, impairing the regenerative potential of cells, and increasing susceptibility to ageing associated diseases. Whether differential methylation of this promoter region of ANRIL or other CpGs sites further upstream also associated with an altered susceptibility to other ageing associated diseases is, as yet, unclear. Thus, these findings suggest that both genetic and epigenetic alterations within ANRIL may have important consequences for future disease risk.

In liposarcoma cells, we found that site directed mutagenesis of CpG sites affected ANRIL and p14ARF promoter activity respectively, and although mutation of a CpG site does not infer that methylation of the CpG would have the same effect, it does clearly suggest that these CpG sequences are important determinants regulating ANRIL and p14ARF expression. Binding of specific protein complexes to sequences within the DMR was also observed in liposarcoma cells, with methylation of CpG 2 increasing protein binding. DNA methylation has generally been associated with reduced transcription factor binding36, but there is now growing evidence that DNA methylation can also enhance transcription factor binding37. Interestingly, multiplexed competitor EMSAs identified ERα binding across CpGs 2-3. ERα plays an important role in maintenance of metabolic homeostasis and insulin sensitivity, with ERα perturbation linked to the metabolic syndrome38. ERα is highly expressed in adipose tissue39, and a reduction in expression is linked to adipocyte hyperplasia and hypertrophy, insulin resistance and glucose intolerance in both sexes40. We found that treating liposarcoma cells with estrogen stimulated expression of ANRIL, and reduced p14ARF expression. While it remains unclear if ANRIL or p14ARF are direct targets of ERα *in vivo* or part of the pathway by which ERα influences adipocyte function, our experiments do suggest that lower DMR methylation would decrease ERα binding and increase adiposity, consistent with studies showing increased adiposity in ERα knock out mice and that ANRIL may be an important component of this pathway.

Limitations of this study relate to the lack of cord, blood and adipose tissue from the same individuals, so we cannot extrapolate how *CDKN2A* methylation in cord tissue may relate to the methylation of *CDKN2A* in adipose or blood in the same individual, and/or whether such epigenetic alterations are causally involved in the development of fat mass. *CDKN2A* methylation was also measured in the 4 cohorts at different ages making exact comparisons between the cohorts more difficult, but the fact that a consistent negative association between *CDKN2A* methylation and measures of adiposity was seen across tissues types and ages suggest that differential methylation of *CDKN2A* may be a robust marker of adiposity.

Interactions of genotype and *in utero* environment best explain the majority of inter-individual differences in umbilical cord DNA methylation41. Therefore *CDKN2A* methylation levels may be specified by an interaction of infant genotype with *in utero* environment or genotype alone (known as a methylation quantitative trait loci (methQTL). MethQTLs are overwhelmingly found *in cis* and the peak enrichment for SNP to CpG distance is within 45bp42. We excluded all known SNPs within the *CDKN2A* DMR (encompassing >45 nt) by direct sequencing; without genome-wide sequencing it is not possible to exclude effects or epistatic interactions of distant SNPs, but the inter-individual variations in *CDKN2A* methylation are most likely to be a product of differential *in utero* environments, perhaps in interaction with individual genotype.

Genome wide association studies (GWAS) have shown that SNPs in the *CDKN2A* locus (typified by rs10757274) and encompassed by ANRIL, but 94KB downstream of the DMR discussed in this paper, were associated with increased susceptibility to frailty, coronary artery disease, myocardial infarction, type 2 diabetes and late onset Alzheimer disease43-50. Interestingly the genetic associations seem independent of obesity49. Disease associated genotype is also associated with ANRIL expression levels, and ANRIL expression also differs relative to disease51-53. Previously Zhuang et al (2012) found that methylation in blood at a locus overlapping with the DMR discussed here, was higher in coronary artery disease compared to controls but methylation was not associated with genotype at rs1075727446. This leads us to speculate that both rs10757274 risk genotype and prenatal environment mediated by differential methylation independently affect ANRIL expression to mediate disease risk.

The finding of a consistent association between *CDKN2A* methylation at birth and later adiposity in Caucasian and Asian cohorts at loci relevant to gene function provides substantial support for a role for epigenetics in mediating the long-term consequences of the early life environment on health, and suggests that altered methylation of CpG loci within the *CDKN2A* locus provide a robust prognostic marker of adiposity trajectory. Moreover these findings suggest a role for the long non-coding RNA ANRIL in the developmental origins of obesity, and identify estrogen as a novel regulator of ANRIL expression.

**Methods**

**Southampton Women’s Survey (SWS): Participants**

The SWS is a prospective study that assessed the diet, body composition, physical activity and social circumstances of a large group of non-pregnant women aged 20-34 years in Southampton, UK. Comprehensive details have been published54. Women who subsequently became pregnant were followed up during pregnancy with serial measurements of fetal size and their offspring studied in infancy and childhood55. There were 1981 women who became pregnant and delivered a live-born singleton infant before the end of 2003. Six infants died in the neonatal period and two had major congenital growth abnormalities, which left 1973 mother-offspring pairs. Triceps skinfold thickness at birth and age 1-year was measured using Holtain skinfold calipers (Holtain Ltd, Crymych, UK). A sub-set of children from the SWS study with dietary data in infancy were invited to take part in follow-up at ages 4 and 6-years to assess their body composition (Table S2). Adiposity measurements were made by dual-energy X-ray absorptiometry (DXA)(Hologic Discovery, paediatric scan mode, Hologic Inc., Bedford, MA)24. Follow-up of the children and sample collection/analysis was carried out under Institutional Review Board approval (Southampton and SW Hampshire Research Ethics Committee 06/Q1702/104) with written informed consent. Clinical investigations were conducted according to the principles expressed in the Declaration of Helsinki.

**Growing Up in Singapore Towards healthy Outcome (GUSTO): Participants**

The GUSTO mother-offspring study56 collected biosamples and measured adiposity in babies born at the KK Women’s and Children’s Hospital (KKH) and the National University Hospital (NUH) in Singapore. Ethical approval for the study was granted by the centralized Institute Review Board (CIRB) and the Domain Specific Review Board (DSRB), the ethics boards of KKH and NUH, respectively (NCT01174875). 1247 women (response rate 61.3%) were recruited; participant characteristics are shown in Table S6. Infant weight was measured to the nearest gram on a calibrated scale (SECA 334, SECA Corp, Hamburg, Germany). Recumbent crown–heel length was measured using an infant mobile measuring mat (SECA 210, SECA Corp Hamburg, Germany). At age 18 months ponderal index (weight/length3) was derived as a measure of adiposity. Triceps and subscapular skinfold thickness were measured using Holtain skinfold calipers.

**BIOCLAIMS study**

The BIOCLAIMS study was a randomised controlled clinical trial of 100 volunteers recruited in Southampton UK 2012-2013. Inclusion criteria were: men or women aged 18-65 yr, BMI 18.5-25 (lean) or BMI 30-40 kg/m2 with waist circumference > 94 cm for men > 80 cm for women (obese), not eating more than one oily fish meal per week and being able to provide written informed consent. Exclusion criteria were: diagnosed diabetes, use of prescribed medicine to control inflammation, blood lipids or blood pressure, use of fish oil or other oil supplements, chronic gastrointestinal problems, pregnancy/planning pregnancy, or participation within another clinical trial. Adipose tissue biopsies were collected from 81 volunteers at baseline (lean n=37, obese n=44) (Table S12).

**The West Australian Pregnancy Cohort (Raine Study): participants**

The Raine Study enrolled pregnant women ≤18th week of gestation (1989–1991) (N = 2,900) through the antenatal clinic at King Edward Memorial Hospital and nearby private clinics in Perth, Western Australia. Detailed clinical assessments were performed at birth. Birth information (including birth weight and height) was obtained from midwife records. The children were followed up at multiple time points including at 17 years of age at which time physical assessments including weight, height, and skin fold assessments were performed as described previously57. Socioeconomic status was assessed by maternal education. Maternal weight and height was measured by a trained midwife at 18 weeks gestation. Early pregnancy weight was obtained at recruitment around 18 weeks gestation. Gestational age was based on the date of the last menstrual period unless there was discordance with ultrasound biometry at the dating scan. The Human Ethics Committees (King Edward Memorial Hospital and/or Princess Margaret Hospital) approved all protocols (RA/4/1/6613). Informed, written consent to participate in the study was obtained from the mother of each child at enrolment and at each subsequent follow-up.

**DNA extraction**

A 5-10 cm segment was cut from the mid portion of each cord, immediately following delivery, flushed with saline to remove fetal blood, flash-frozen in liquid nitrogen and stored at −80°C until required for DNA isolation. Genomic DNA was prepared from umbilical cord and cord blood by a standard high salt method, and from adipose tissue using the QIAamp DNA mini kit (Qiagen, Germany).

**Whole genome methylation analysis**

Genomic DNA from umbilical cord samples was obtained from 21 children from the SWS cohort, chosen to represent a range of %fat between the 5th and 95th percentiles for this population measured by DXA at age-6 years. DNA methylation levels were quantified using Agilent Human Promoter Whole-Genome ChIP-on-chip array (G4489A), and analysed using Bayesian Tool for Methylation Analysis (BATMAN)16 as previously described58. An overview of the study design in shown in Figure 1A.

**Statistical tests to identify Differentially Methylated Regions (DMRs)**

Percentage methylation values at each 100nt region were subjected to robust regression analysis percent fat to correct for heteroscedasticity 59. Fisher Exact tests were performed to identify larger chromosomal regions DMRs that tiled sequentially on the array. These regions were tested for significant enrichment of differential methylation amongst the 100nt regions, within their span. This principal is similar to that of 60 but is especially designed for the custom array design. The cut offs used to select DMRs were designed to be a stringent filter to prioritise genes for the pathway analysis.

**Test for robustness to failed probe signals**

It was observed that a portion of the probes included in the raw data had a log2 value approaching 0. These probes were assumed to be failed probes and were removed from the data set and the modified dataset was subjected to the BATMAN algorithm. Any DMRs not robust between the two data sets were removed from consideration. A surrogate variable analysis (SVA)18 similar to the “reference-free” analysis suggested by Houseman et al.19 was run to check for any confounding effects of differences in cellular heterogeneity.

**IPA analysis**

Gene pathway analysis was carried out using Ingenuity Pathway Analysis software (Qiagen), with the design of the array set as the background in the pathway analysis. The gene list of identified DMRs from the BATMAN analysis was used to generate gene networks via a core analysis based upon the Ingenuity Pathways Knowledge Base.

**Statistical analysis**

Statistical analysis on the SWS was carried out using Stata (Statacorp) versions 11.2 and 12.1. Histograms of all continuous variables were plotted to check for normality. The distributions of some measures of adiposity were skewed and therefore transformed using a loge transformation. Conditional sex-specific abdominal circumference growth velocities (Z-scores) were calculated from antenatal ultrasound measurements as described previously55. Velocities of prenatal and infant growth were calculated from change in size adjusted for gestation or age, as appropriate. DXA adiposity measurements were calculated without including the child’s head to minimise the effect of head movement on the measurement. Regression models were built using CpG methylation as the predictor and child’s adiposity measurement (at 4 or 6 years) as the outcome, and of conditional abdominal circumstance growth velocity from 34 weeks gestation to birth as the predictor and cord CpG methylation as the outcome. Models were adjusted for child’s sex and age as appropriate for each time point. Offspring adiposity was measured as %fat and total fat in grams, converted to Z-scores to facilitate interpretation of the effect size, and methylation measurements as %; the regression coefficient can therefore be interpreted as the standard deviation change in %fat (or total fat) for each % change in methylation. Results are presented as regression coefficients (β), which represent the (mean) change in outcome for a one unit (%) change in methylation, and their associated P-values. Analyses for validation of the array results were carried out on the full range of data, without grouping.

As there was a strong correlation between methylation of the individual CpGs within ANRIL, and because the number of tests carried out was modest in comparison with genome-wide approaches, Bonferroni or Benjamini-Hochberg false discovery rate corrections for multiple testing would not be appropriate61. Instead a data reduction approach was employed by investigating the correlations between methylation at the 9 CpG sites, identifying those which cluster together statistically, and choosing the CpG with the highest median absolute deviation (MAD) score to represent that cluster. In both the SWS and GUSTO cohorts, the clustering of CpGs sites was similar with CpGs 1-2, 3 4-8 clustering. The exception was CpG9, which clustered with CpG 4-8 in the SWS cohort but separately in the GUSTO cohort. We therefore used a clustering which was appropriate across both cohorts, and grouped the 9 CpG sites into 4 clusters CpGs 1-2, 3, 4-8 and 9, represented by CpGs 2, 3, 7 and 9.

Linear regression was used to analyse associations between DNA methylation levels, gene expression and infant adiposity measures in the GUSTO cohort. DNA methylation and infant adiposity measures were adjusted for sex, ethnicity, maternal age, mode of delivery and cell type. Cell type was corrected for using cellular proportions estimated from a reference panel’s cell-specific methylation dataset62,63. Experimental batches were accounted for as a covariate. Similar linear regressions were done to assess the relationship between methylation and gene expression. All statistical analyses in the GUSTO cohort were performed in R (version 2.15.3).

Linear regression was used to analyse association between DNA methylation levels and BMI in the Raine cohort. The distribution of BMI in this cohort was positively skewed and therefore log-transformed. Multivariate linear regression was adjusted for age and sex. Differences in cellular heterogeneity in blood was assessed Cell type

**Pyrosequencing**

The levels of DNA methylation at the *CDKN2A* DMR in DNA extracted from umbilical cord was measured by sodium bisulfite pyrosequencing as previously described58. Methylation ranges are shown in Table S13 and primers in Table S14.

**Real-time PCR in the GUSTO cohort**

RNA was extracted from whole umbilical cords obtained in the GUSTO study, using the RNeasy Mini Kit (Qiagen) as per manufacturer’s guidelines. cDNA was prepared using the Hi-Capacity cDNA Reverse Transcription Kit (Life Technologies), and qPCR reactions run in triplicate with Power SYBR (Life Technologies) on a ABI 7900HT as per manufacturer’s guidelines. Primer sequences are shown in Table S14 Primers to detect circular transcripts are described in64. All Ct values were normalized to the geometric mean of TOP1 and PPIA reference amplicons, and thereafter referred to as dCt (delta-Ct) values. The dCt value was used in all subsequent regressions and statistical analyses, since assignment to a calibrator necessary for the exponential determination of fold change would be arbitrary and inappropriate for a longitudinal-type population with continuous characteristics.

**Cloning of promoter regions**

Two sets of PCR primers were used. The first set amplified the ANRIL promoter (-926 to +20 relative to ANRIL TSS); a HindIII restriction site was added to the forward primer, and an NcoI restriction site to the reverse primer for cloning into pGL Basic (Promega, UK) to create pGL -951. The second PCR primer pair amplified a region containing the DMR, immediately adjacent to the already cloned ANRIL promoter region (-1281 to -925); a KpnI restriction site was added to the forward primer, and a HindIII restriction site to the reverse primer for cloning into pGL -951. The completed plasmid, pGL ANRIL, contained the full genomic sequence from -1281 to +20 of the ANRIL promoter with a HindIII site inserted after the DMR to allow its subsequent removal. All PCR amplification was carried out using Hot Star High Fidelity DNA polymerase (QIAGEN). Primers are listed in Table S14. The base pair sequence of the cloned region was confirmed by sequencing (GATC, Germany). The p14ARF promoter region was produced by GeneArt (Applied Biosystems), and subsequently cloned into pGL3 Basic.

**PCR mutagenesis**

Mutagenesis primers were designed using QuikChange Primer Design. PCR was carried out using the SequalPrep™ Long PCR Kit (Life Technologies A10498) following manufacturers guidelines. Mutagenesis was confirmed by sequencing (GATC, Germany).

**Cell culture and transfection**

SW872 cells were cultured in 24well plates (DMEM 4.5g glucose, 10% FBS, 1%P/S) for 24hrs prior to transfection. 500ng plasmid DNA was transfected (six replicates per transfection). pGL CMV Renilla (Promega UK) was co-transfected as a control. Transfections were carried out using FuGENE HD (Switchgear Genomics USA) following manufacturers’ guidelines. Transfected cells were cultured for 48hrs prior to harvesting. Luciferase assays were carried out using the Dual-Luciferase® Reporter Assay System (Promega UK), on a VarioSkan Flash Luminometer (ThermoScientific). For estrogen treatment, cells were cultured in phenol-free media and charcol-stripped FBS for 48hrs prior to addition of 10nM E2 (Sigma E2758). Cells were cultured for 72hrs then harvested for RNA.

**Realtime PCR in SW872 cells**

RNA was extracted from whole umbilical cords obtained in the GUSTO study, using the RNeasy Mini Kit (Qiagen) as per manufacturer’s guidelines. cDNA was prepared using Enhanced AMV-RT (Sigma) after DnaseI treatment (Sigma). Realtime PCR was carried out in gene expression master mix (Life technologies), and gene expression assayed for p14 and exons 5-6 for ANRIL (Life technologies p14 (Hs99999189, Hs04259476). Anril unspliced used custom primers (Table S14) amplifying a region of intron 1.

**Electrophoretic mobility shift assays**

EMSA were carried out on nuclear extracts from SW872 cells as previously described37. DNA oligonucleotides (Sigma Aldrich) are listed in Table S14.

**Acknowledgements**

We thank the EpiGen Operational Management Group for their project management and Dr Irma Silva Zolezzi, Nestlé Research Center, for helpful discussion of the manuscript. We also thank all the families that took part in The Raine study and the Raine Study team, which includes data collectors, cohort managers, clerical staff, research scientists, and volunteers. This work was supported by the Raine Medical Research Foundation; Healthway, Western Australia; The Telethon Kids Institute, University of Western Australia (UWA); Faculty of Medicine, Dentistry and Health Sciences (UWA); Women and Infants Research Foundation (UWA); Curtin University; and The Australian National Health and Medical Research Council (NHMRC). RCH is supported by a NHMRC Fellowship.

The EpiGen study group includes; Philip Baker, Graham Burdge, Chong Yap Seng, Cyrus Cooper, Wayne Cutfield, Keith Godfrey, Nicholas Harvey, Joanna Holbrook, Mary Chong Foong-Fong, Neerja Karnani, Lee Yung Seng, Karen Lillycrop, Walter Stunkel and Allan Shepherd. The GUSTO study group includes Pratibha Agarwal, Arijit Biswas, Choon Looi Bong, Birit FP Broekman, Shirong Cai, Jerry Kok Yen Chan, Yiong Huak Chan, Cornelia Yin Ing Chee, Helen Y. H Chen, Yin Bun Cheung, Audrey Chia, Amutha Chinnadurai, Chai Kiat Chng, Mary Foong-Fong Chong, Shang Chee Chong, Mei Chien Chua, Chun Ming Ding, Eric Andrew Finkelstein, Doris Fok, Marielle Fortier, Anne Eng Neo Goh, Yam Thiam Daniel Goh, Joshua J. Gooley, Wee Meng Han, Mark Hanson, Christiani Jeyakumar Henry, Chin-Ying Hsu, Hazel Inskip, Jeevesh Kapur, Kenneth Kwek, Ivy Yee-Man Lau, Bee Wah Lee, Ngee Lek, Sok Bee Lim, Yen-Ling Low, Iliana Magiati, Lourdes Mary Daniel, Cheryl Ngo, Krishnamoorthy Naiduvaje, Wei Wei Pang, Anqi Qiu, Boon Long Quah, Victor Samuel Rajadurai, Mary Rauff, Salome A. Rebello, Jenny L. Richmond, Anne Rifkin-Graboi, Lynette Pei-Chi Shek, Allan Sheppard, Borys Shuter, Leher Singh, Walter Stunkel, Lin Lin Su, Kok Hian Tan, Oon Hoe Teoh, Hugo P S van Bever, Rob M. van Dam, Inez Bik Yun Wong, P. C. Wong, George Seow Heong Yeo.

**Funding Sources**

This work was supported by funding from the Medical Research Council (MC\_UU\_12011/4, MC\_U147585827 and MC\_ST\_U12055) British Heart Foundation (RG/15/17/3174 and RG/07/009), Arthritis Research UK, National Osteoporosis Society, International Osteoporosis Foundation, Cohen Trust, Nestec, NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, the Singapore National Research Foundation under its Translational and Clinical Research (TCR) Flagship Programme administered by the Singapore Ministry of Health’s National Medical Research Council (NMRC), Singapore- NMRC/TCR/004-NUS/2008; NMRC/TCR/012-NUHS/2014. The BIOCLAIMS study was supported by the European Commission Framework 7 Programme (Grant agreement no. 244995). Additional funding was provided by the Singapore Institute for Clinical Sciences, Agency for Science Technology and Research (A\*STAR), Singapore. KMG is supported by the European Union's Seventh Framework Programme (FP7/2007-2013), project EarlyNutrition under grant agreement n°289346.

**Conflicts of interest**

The following authors have no financial interest related to this work: K.L., R.M., C.C., A.T., R.C-H., S.B., P.C., E.G., E.C., P.T., B.S., S.L., Y-C.C., X.L., Y.W., G.B., C.C., H.I., N.K., J.H., C.E.C., C.P.C., Y.P., Y.L., Y.C., P.M., L.B., R-C.H., P.G., N.H., M.H., J.D., P.D.G. Both P.C.C and K.M.G have received travel reimbursement for speaking at conferences sponsored by companies selling nutritional and pharmaceutical products. This work was supported in part by a grant from Nestec.

**Authors’ contributions**

R.M., R.C-H., P.C., E.G., E.C and C.Y.C carried out the molecular epigenetic studies. R.M., B.S., S.L., Y-C.C., X.L and Y.W., participated in the analysis. R.M, K.L., K.M.G and S.B drafted the manuscript. A.T., P.M., L.B., P.T J.H and S.B performed the statistical analysis and prepared the tables/figures. K.L., K.M.G., C.C., G.B., H.I., N.K., J.H., C.E.C., C.P.C., Y.P., Y.L., Y.C., N.H and P.C.C participated in the study design and/or collected the samples/physiological measurements. K.L., K.M.G, C.C., M.H., P.D.G conceived of the study, its design, and its coordination. All authors helped draft the manuscript, participated in manuscript editing and read/approved the final manuscript.

**References**

1. Frayling, T.M.*, et al.* A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. *Science* **316**, 889-894 (2007).

2. Loos, R.J.*, et al.* Common variants near MC4R are associated with fat mass, weight and risk of obesity. *Nature genetics* **40**, 768-775 (2008).

3. Thorleifsson, G.*, et al.* Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity. *Nature genetics* **41**, 18-24 (2009).

4. Wellcome Trust Case Control, C.*, et al.* Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. *Nature* **464**, 713-720 (2010).

5. Godfrey, K.M. & Barker, D.J. Fetal programming and adult health. *Public Health Nutr.* **4**, 611-624 (2001).

6. Roseboom, T., de, R.S. & Painter, R. The Dutch famine and its long-term consequences for adult health. *Early Hum.Dev.* **82**, 485-491 (2006).

7. Catalano, P.M. & Ehrenberg, H.M. The short- and long-term implications of maternal obesity on the mother and her offspring. *BJOG : an international journal of obstetrics and gynaecology* **113**, 1126-1133 (2006).

8. Robinson, S.M.*, et al.* Modifiable early-life risk factors for childhood adiposity and overweight: an analysis of their combined impact and potential for prevention. *The American journal of clinical nutrition* **101**, 368-375 (2015).

9. Pettitt, D.J.*, et al.* Abnormal glucose tolerance during pregnancy in Pima Indian women. Long-term effects on offspring. *Diabetes* **40 Suppl 2**, 126-130 (1991).

10. Bertram, C.E. & Hanson, M.A. Animal models and programming of the metabolic syndrome. *Br.Med.Bull.* **60**, 103-121 (2001).

11. Poston, L. Developmental programming and diabetes - The human experience and insight from animal models. *Best practice & research. Clinical endocrinology & metabolism* **24**, 541-552 (2010).

12. Lillycrop, K.A.*, et al.* Induction of altered epigenetic regulation of the hepatic glucocorticoid receptor in the offspring of rats fed a protein-restricted diet during pregnancy suggests that reduced DNA methyltransferase-1 expression is involved in impaired DNA methylation and changes in histone modifications. *Br.J.Nutr.* **97**, 1064-1073 (2007).

13. Heijmans, B.T.*, et al.* Persistent epigenetic differences associated with prenatal exposure to famine in humans. *Proc.Natl.Acad.Sci.U.S A* **105**, 17046-17049 (2008).

14. Godfrey, K.M.*, et al.* Epigenetic gene promoter methylation at birth is associated with child's later adiposity. *Diabetes* **60**, 1528-1534 (2011).

15. Clarke-Harris, R.*, et al.* Peroxisomal proliferator activated receptor-gamma-co-activator-1alpha promoter methylation in blood at 5-7 years predicts adiposity from 9 to 14 years (EarlyBird 50). *Diabetes* (2014).

16. Down, T.A.*, et al.* A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. *Nat.Biotechnol.* **26**, 779-785 (2008).

17. Abella, A.*, et al.* Cdk4 promotes adipogenesis through PPARgamma activation. *Cell Metab* **2**, 239-249 (2005).

18. Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E. & Storey, J.D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* **28**, 882-883 (2012).

19. Houseman, E.A., Molitor, J. & Marsit, C.J. Reference-free cell mixture adjustments in analysis of DNA methylation data. *Bioinformatics* **30**, 1431-1439 (2014).

20. Smith, A.J. & Humphries, S.E. Characterization of DNA-binding proteins using multiplexed competitor EMSA. *J Mol Biol* **385**, 714-717 (2009).

21. Turner, E.C. & Kinsella, B.T. Estrogen increases expression of the human prostacyclin receptor within the vasculature through an ERalpha-dependent mechanism. *J Mol Biol* **396**, 473-486 (2010).

22. Shu, F.J., Sidell, N., Yang, D. & Kallen, C.B. The tri-nucleotide spacer sequence between estrogen response element half-sites is conserved and modulates ERalpha-mediated transcriptional responses. *The Journal of steroid biochemistry and molecular biology* **120**, 172-179 (2010).

23. Anolik, J.H., Klinge, C.M., Hilf, R. & Bambara, R.A. Cooperative binding of estrogen receptor to DNA depends on spacing of binding sites, flanking sequence, and ligand. *Biochemistry* **34**, 2511-2520 (1995).

24. Crozier, S.R.*, et al.* Maternal vitamin D status in pregnancy is associated with adiposity in the offspring: findings from the Southampton Women's Survey. *The American journal of clinical nutrition* **96**, 57-63 (2012).

25. Crozier, S.R.*, et al.* Weight gain in pregnancy and childhood body composition: findings from the Southampton Women's Survey. *The American journal of clinical nutrition* **91**, 1745-1751 (2010).

26. Lillycrop, K.A.*, et al.* Feeding pregnant rats a protein-restricted diet persistently alters the methylation of specific cytosines in the hepatic PPARalpha promoter of the offspring. *British Journal of Nutrition* **100**, 278-282 (2008).

27. Nilsson, K. & Landberg, G. Subcellular localization, modification and protein complex formation of the cdk-inhibitor p16 in Rb-functional and Rb-inactivated tumor cells. *Int J Cancer* **118**, 1120-1125 (2006).

28. Jin, X., Nguyen, D., Zhang, W.W., Kyritsis, A.P. & Roth, J.A. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. *Cancer Res* **55**, 3250-3253 (1995).

29. Jacobs, J.J., Kieboom, K., Marino, S., DePinho, R.A. & van Lohuizen, M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. *Nature* **397**, 164-168 (1999).

30. Pomerantz, J.*, et al.* The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. *Cell* **92**, 713-723 (1998).

31. Zhang, Y., Xiong, Y. & Yarbrough, W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. *Cell* **92**, 725-734 (1998).

32. Kim, W.Y. & Sharpless, N.E. The regulation of INK4/ARF in cancer and aging. *Cell* **127**, 265-275 (2006).

33. Matheu, A.*, et al.* Anti-aging activity of the Ink4/Arf locus. *Aging Cell* **8**, 152-161 (2009).

34. Aguilar, V. & Fajas, L. Cycling through metabolism. *EMBO molecular medicine* **2**, 338-348 (2010).

35. Dali-Youcef, N.*, et al.* Adipose tissue-specific inactivation of the retinoblastoma protein protects against diabesity because of increased energy expenditure. *Proceedings of the National Academy of Sciences of the United States of America* **104**, 10703-10708 (2007).

36. Tate, P.H. & Bird, A.P. Effects of DNA methylation on DNA-binding proteins and gene expression. *Curr Opin Genet Dev* **3**, 226-231 (1993).

37. Clarke-Harris, R.*, et al.* PGC1alpha promoter methylation in blood at 5-7 years predicts adiposity from 9 to 14 years (EarlyBird 50). *Diabetes* **63**, 2528-2537 (2014).

38. Hevener, A.L., Clegg, D.J. & Mauvais-Jarvis, F. Impaired estrogen receptor action in the pathogenesis of the metabolic syndrome. *Mol Cell Endocrinol* **418 Pt 3**, 306-321 (2015).

39. Mizutani, T.*, et al.* Identification of estrogen receptor in human adipose tissue and adipocytes. *The Journal of clinical endocrinology and metabolism* **78**, 950-954 (1994).

40. Mauvais-Jarvis, F., Clegg, D.J. & Hevener, A.L. The role of estrogens in control of energy balance and glucose homeostasis. *Endocrine reviews* **34**, 309-338 (2013).

41. Teh, A.L.*, et al.* The effect of genotype and in utero environment on interindividual variation in neonate DNA methylomes. *Genome research* **24**, 1064-1074 (2014).

42. Gibbs, J.R.*, et al.* Abundant Quantitative Trait Loci Exist for DNA Methylation and Gene Expression in Human Brain. *PLoS Genet* **6**, e1000952 (2010).

43. Melzer, D.*, et al.* A common variant of the p16(INK4a) genetic region is associated with physical function in older people. *Mech Ageing Dev* **128**, 370-377 (2007).

44. Cunnington, M.S., Santibanez Koref, M., Mayosi, B.M., Burn, J. & Keavney, B. Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression. *PLoS genetics* **6**, e1000899 (2010).

45. Grarup, N.*, et al.* Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. *Diabetes* **56**, 3105-3111 (2007).

46. Zhuang, J.*, et al.* Methylation of p15INK4b and expression of ANRIL on chromosome 9p21 are associated with coronary artery disease. *PloS one* **7**, e47193 (2012).

47. Zeggini, E.*, et al.* Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. *Science* **316**, 1336-1341 (2007).

48. Scott, L.J.*, et al.* A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science* **316**, 1341-1345 (2007).

49. Broadbent, H.M.*, et al.* Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. *Hum Mol Genet* **17**, 806-814 (2008).

50. Congrains, A.*, et al.* Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. *Atherosclerosis* **220**, 449-455 (2012).

51. Zhao, W.*, et al.* The cis and trans effects of the risk variants of coronary artery disease in the Chr9p21 region. *BMC Med Genomics* **8**, 21 (2015).

52. Shanker, J., Arvind, P., Jambunathan, S., Nair, J. & Kakkar, V. Genetic analysis of the 9p21.3 CAD risk locus in Asian Indians. *Thromb Haemost* **111**, 960-969 (2014).

53. Bochenek, G.*, et al.* The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. *Hum Mol Genet* **22**, 4516-4527 (2013).

54. Inskip, H.M.*, et al.* Cohort profile: The Southampton Women's Survey. *International journal of epidemiology* **35**, 42-48 (2006).

55. Pike, K.C.*, et al.* Patterns of fetal and infant growth are related to atopy and wheezing disorders at age 3 years. *Thorax* **65**, 1099-1106 (2010).

56. Soh, S.E.*, et al.* Cohort Profile: Growing Up in Singapore Towards healthy Outcomes (GUSTO) birth cohort study. *International journal of epidemiology* (2013).

57. Huang, R.C., Burrows, S., Mori, T.A., Oddy, W.H. & Beilin, L.J. Lifecourse Adiposity and Blood Pressure Between Birth and 17 Years Old. *American journal of hypertension* **28**, 1056-1063 (2015).

58. Lillycrop, K.A.*, et al.* Association between perinatal methylation of the neuronal differentiation regulator HES1 and later childhood neurocognitive function and behaviour. *International journal of epidemiology* (2015).

59. Barton, S.J., Crozier, S.R., Lillycrop, K.A., Godfrey, K.M. & Inskip, H.M. Correction of unexpected distributions of P values from analysis of whole genome arrays by rectifying violation of statistical assumptions. *BMC genomics* **14**, 161 (2013).

60. Jaffe, A.E.*, et al.* Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. *Int.J.Epidemiol.* **41**, 200-209 (2012).

61. Goeman, J.J. & Solari, A. Multiple hypothesis testing in genomics. *Stat Med* **33**, 1946-1978 (2014).

62. Gutierrez-Arcelus, M.*, et al.* Passive and active DNA methylation and the interplay with genetic variation in gene regulation. *eLife* **2**, e00523 (2013).

63. Houseman, E.A.*, et al.* DNA methylation arrays as surrogate measures of cell mixture distribution. *BMC Bioinformatics* **13**, 86 (2012).

64. Burd, C.E.*, et al.* Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. *PLoS genetics* **6**, e1001233 (2010).

**Figure 1** (A) An overview of the study. (B) The top network enriched amongst the DMRs was DNA replication, recombination and repair.

**(A)**







**(B)**

**Figure 2. Association between *CDKN2A* DMR at birth and adiposity in childhood.** (A) The DMR identified within *CDKN2A* (Chr9:21,993,565-21,993,764 (hg19). Percentage adiposity values for SWS subjects were divided into three groups from low (group 1) to high (group 3) %fatmass. The Y-axis shows absolute %methylation difference between groups 1 and 3. X-axis shows chromosomal coordinates (hg19). Light and dark grey circles represent start and end of each 100 nucleotide region returned from BATMAN, respectively. 100 nucleotide regions in the dotted box were found to have >20% absolute methylation difference between groups 1 and 3 and these were the regions selected for pyrosequencing in the extended sample set. The lower panel shows the positions of gene transcripts. (B) The concordance of methylation values with percent body fat for *CDKN2A* using discovery data from the MBD whole genome promoter array. The X-axis shows percent body fat and y-axis shows % methylation as estimated by BATMAN. Percentage methylation values at each 100nt region was subjected to robust regression analysis against % fat mass at 6 years of age. To illustrate the association found, sample data points are coloured by percent body fat group groups (red = low, lowest percent body fat; blue = medium, medium percent body fat; green = high, highest percent body fat.

**.**

(A) The *CDKN2A* DMR



Chr9: 21993565-21993664 CpG 1-3

Chr9: 21993665-21993764 CpG 4-9

(B)

**Figure 3. CpG Clustering.** Spearman correlation of methylation levels at CpGs 1-9 within the ANRIL promoter. Four distinct clusters are defined: 1-2, 3, 4-8 and 9. (A) correlations in the SWS cohort. (B) correlations in the GUSTO cohort. (C) Median absolute deviation (MAD) scores within the 4 clusters in SWS Cohort.



(B) GUSTO cohort correlations

(A) SWS cohort correlations





(C) SWS cohort MAD scores

**Figure 4. The role of CpGs in the *CDKN2A* DMR** (A) Adipose methylation levels, lean vs obese groups, controlling for sex and age.(B) The ANRIL promoter and 5’ portion of the p14ARF gene were fused to the luciferase gene, and site directed mutagenesis of CpG sites performed. Constructs were transfected into the liposarcoma cell line SW-872 and luciferase activity measured. 6 technical replicates were undertaken per construct, per experiment and results combined from two independent experiments \*p <0.05, \*\*p <0.01, \*\*\*p <0.005, \*\*\*\*p <0.001. (C) EMSAs using SW-872 nuclear extract to examine differential binding within the DMR. (D) Varying levels of non-radiolabelled competitor was used to compete out binding to the radiolabelled probe covering CpG sites 2-3. (E) Unmethylated and methylated competitors were used to compare the effect of methyl groups on binding affinity (methylated at CpG2). (F) Binding of the 2-3 competitor compared using a radiolabelled probe methylated at CpG2. (F) CpG2-3 and ERα cold competitors were used to compete out binding of radiolabelled ERα probe. (G) ERE identified in the CpG2-3 region of the *CDKN2A* DMR, figure shows consensus ERE derived from Shu *et al.* top 643 confirmed EREs. (H) Expression of ANRIL and p14 in SW872 cells treated with 10nM β-Estradiol for 72hrs. ANRIL spliced primers detect Exons 5-6.



**Table 1. Association between *CDKN2A* DMR methylation and percentage and total fat mass in the SWS cohort.** Associations between % and total fat mass at birth, 4 years and 6 years for *CDKN2A*. **\* p = 0.05-0.01. \*\* p ≤ 0.01**; n=number of subjects, β=regression coefficient. Adjusted for sex, maternal age at birth and mode of delivery.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ***CDKN2A*** | **4 yr. DXA: Percentage fat** | | | **4 yr. DXA: total fat** | | | **6 yr. DXA: Percentage fat** | | | **6 yr. DXA: total fat** | | |
| **cluster** | **n** | **β** | **p-value** | **n** | **β** | **p-value** | **n** | **β** | **p-value** | **n** | **β** | **p-value** |
| **1-2** | 215 | -0.09 | **0.007\*\*** | 215 | -0.005 | **0.003\*\*** | 204 | -0.004 | **0.003\*\*** | 205 | -0.005 | **0.011\*** |
| **3** | 192 | -0.074 | 0.111 | 192 | -0.005 | **0.024\*** | 184 | -0.005 | **0.007\*\*** | 184 | -0.007 | **0.014\*** |
| **4-8** | 244 | -0.076 | **0.04\*** | 244 | -0.004 | **0.015\*** | 228 | -0.003 | **0.042\*** | 229 | -0.006 | **0.016\*** |
| **9** | 218 | -0.074 | 0.089 | 218 | -0.005 | **0.011\*** | 203 | -0.003 | 0.122 | 204 | -0.007 | **0.022\*** |

**Table 2. Association between *CDKN2A* methylation at birth and triceps skinfold thickness in childhood.** Methylation levels of the 9 CpG dinucleotides within the *CDKN2A* DMR were related to triceps skinfold thickness in (A) the SWS cohort at birth and 1-year (linear regression, adjusted for sex), and (B) the GUSTO cohort at day 7 and 18 months (adjusted for sex, ethnicity and cell type); n=number of subjects, b=regression coefficient. **\* p = 0.05-0.01. \*\* p ≤ 0.01.**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **(A)** |  |  |  |  |  | **(B)** |  |  |  |  |
| **SWS cohort** | | **Triceps skinfold thickness** | | |  | **GUSTO cohort** | | **Triceps skinfold thickness** | | |
| **cluster** | **Timepoint** | **n** | **β** | **p-value** |  | **cluster** | **Timepoint** | **n** | **β** | **p-value** |
| **1-2** | **Birth** | 258 | 0.001 | 0.406 |  | **1-2** | **day 7** | 242 | -0.592 | 0.84 |
| **1 year** | 258 | -0.032 | **0.039\*** |  | **18 month** | 215 | 3.872 | 0.29 |
| **3** | **Birth** | 233 | 0.001 | 0.611 |  | **3** | **day 7** | 217 | -9.557 | **0.004\*\*** |
| **1 year** | 235 | -0.037 | 0.068 |  | **18 month** | 195 | -2.452 | 0.56 |
| **4-8** | **Birth** | 295 | 0.002 | 0.119 |  | **4-8** | **day 7** | 282 | -1.378 | 0.38 |
| **1 year** | 295 | -0.04 | **0.014\*** |  | **18 month** | 253 | -0.021 | 0.99 |
| **9** | **Birth** | 267 | 0.001 | 0.436 |  | **9** | **day 7** | 204 | -3.718 | 0.17 |
| **1 year** | 266 | -0.028 | 0.157 |  | **18 month** | 175 | 2.094 | 0.54 |

**Table 3. Gene expression correlates with *CDKN2A* DMR methylation in the GUSTO cohort.** Methylation levels of the 9 *CDKN2A* DMR CpGs were correlated with expression levels (dCt values from RT-PCR) of the different ANRIL transcript variants, p14ARF and p16INK4a using linear regression, adjusted for gender and ethnicity; n=no. of subjects.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **CpG cluster** | **ANRIL (Linear)** | | **ANRIL (Circular)** | | **ANRIL (Unspliced)** | | **p14ARF** | | **p16INK4a** | |
| **n** | **p-value** | **n** | **p-value** | **n** | **p-value** | **n** | **p-value** | **n** | **p-value** |
| **1-2** | 174 | 0.06 | 116 | 0.539 | 174 | 0.70 | 174 | 0.98 | 137 | 0.07 |
| **3** | 167 | 0.24 | 110 | 0.940 | 167 | 0.27 | 167 | 0.78 | 130 | 0.06 |
| **4-8** | 180 | **0.02** | 118 | 0.051 | 180 | 0.06 | 180 | 0.91 | 142 | 0.95 |
| **9** | 106 | 0.16 | 81 | 0.111 | 106 | **0.02** | 107 | **0.05** | 91 | **0.01** |

**Table 4. Association between *CDKN2A* DMR methylation is with anthropometry at 17 years in the RAINE cohort.** Methylation levels of the 9 CpG dinucleotides within the *CDKN2A* DMR were associated with BMI, (linear regression adjusted for sex, age of child, and estimated cell counts - top two principal components); n=number of subjects, b=regression coefficient. BMI was natural log transformed.

|  |  |  |  |
| --- | --- | --- | --- |
|  | | **BMI**  **(age and sex adjusted only)** | |
| **CpG cluster** | **n** | **β** | **P value** |
| CpG 1-2 | 758 | 0.004 | 0.98 |
| CpG3 | 723 | -0.004 | 0.060 |
| CpG 4-8 | 740 | -0.004 | **0.008** |
| CpG9 | 760 | -0.004 | **0.006** |

**Supplementary Table 1. Association between conditional abdominal circumference growth Z-score from 34 weeks gestation to birth and umbilical cord *CDKN2A* methylation in the SWS.**

|  |  |  |  |
| --- | --- | --- | --- |
| ***CDKN2A* CpG** | **n** | **Abdominal circumference sex-specific LMS z-score growth from week 34 to birth** | |
| **Beta** | **P value** |
| **CpG 1** | 135 | 0.016 | 0.051 |
| **CpG 2** | 131 | 0.014 | 0.11 |
| **CpG 3** | 117 | 0.03 | **0.008\*\*** |
| **CpG 4** | 154 | 0.018 | **0.034\*** |
| **CpG 5** | 152 | 0.019 | **0.024\*** |
| **CpG 6** | 152 | 0.015 | 0.077 |
| **CpG 7** | 151 | 0.018 | 0.071 |
| **CpG 8** | 139 | 0.018 | **0.046\*** |
| **CpG 9** | 134 | 0.018 | 0.126 |

**Supplementary Table 2. Characteristics of the SWS study participants**

|  |  |  |
| --- | --- | --- |
| **Characteristic** | **Group/number** | **% or median (inter-quartile range)** |
| **Mother** |  |  |
| **Qualification level** | None | 0.9% |
|  | CSE | 9.9% |
|  | O levels | 27.0% |
|  | A levels | 26.4% |
|  | HND | 9.1% |
|  | Degree | 27.6% |
| **Social class** | Professional | 6.4% |
|  | Management/technical | 42.2% |
|  | Skilled non-manual | 33.2% |
|  | Skilled manual | 6.9% |
|  | Partly skilled | 10.4% |
|  | Unskilled | 0.9% |
| **Current smoker** | No | 77.0% |
|  | Yes | 23.0% |
| **Parity** | Primiparous | 47.7% |
|  | Multiparous | 52.3% |
| **Age at birth of child** | 352 | 30.7 (28.1 to 33.4) |
| **Early pregnancy BMI** | 279 | 24.8 (22.7 to 28.2) |
| **Offspring** |  |  |
| **Sex** | Male | 52.8% |
|  | Female | 47.2% |
| **Birthweight (kg)** | 349 | 3.4 (3.2 to 3.8) |
| **Gestation (wks.)** | 352 | 40.0 (39.0 to 40.9) |
| **Total fat (g) at birth** | 147 | 497.9 (364.3 to 644.3) |
| **Total fat (kg) at 4 years** | 283 | 4.0 (3.4 to 4.8) |
| **Total fat (kg) at 6 years** | 264 | 4.5 (3.6 to 6.0) |
| **%fat at birth** | 147 | 14.3 (11.6 to 17.3) |
| **%fat at 4 years** | 283 | 27.8 (24.3 to 32.5) |
| **%fat at 6 years** | 263 | 24.2 (19.9 to 29.7) |
| **Height (cm) at 4 years** | 350 | 103.9 (101.2 to 106.9) |
| **Height (cm) at 6 years** | 282 | 120 (116.7 to 124.3) |

**Supplementary Table 3.** Genes containing differentially methylated regions of interests (DMRs) identified from the MBD array using Fisher Exact tests, sorted by Fisher Exact test p-value.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Gene** | **Chr** | **p value** | **Gene** | **Chr** | **p value** |
| FEN1 | 11 | 1.00E-06 | SLC39A6 | 18 | 0.003518 |
| CCND1 | 11 | 1.00E-06 | BRSK2 | 11 | 0.003586 |
| GAPDH | 12 | 1.00E-06 | PRRC1 | 5 | 0.003859 |
| NGB | 14 | 1.00E-06 | C14orf142 | 14 | 0.003905 |
| GUSB | 7 | 1.00E-06 | APOL5 | 22 | 0.003905 |
| CCDC147 | 10 | 6.00E-06 | WWC2 | 4 | 0.004009 |
| ZNF17 | 19 | 6.00E-06 | DDX10 | 11 | 0.004046 |
| GATA6 | 18 | 2.40E-05 | DPF3 | 14 | 0.004774 |
| MPV17 | 19 | 2.90E-05 | GNG4 | 1 | 0.004802 |
| AKAP8 | 19 | 3.20E-05 | LAMA5 | 20 | 0.005051 |
| TNFRSF19 | 13 | 4.20E-05 | DSCR9 | 21 | 0.005272 |
| ABCA4 | 1 | 4.70E-05 | RNF43 | 17 | 0.005397 |
| TMEM116 | 12 | 5.50E-05 | DGKZ | 11 | 0.005776 |
| SETD4 | 21 | 5.60E-05 | TRIM13 | 13 | 0.006775 |
| SEZ6 | 17 | 6.50E-05 | FAM174B | 15 | 0.006871 |
| ZNF56 | 19 | 7.60E-05 | TOP2A | 17 | 0.007924 |
| APP | 21 | 9.30E-05 | NGFR | 17 | 0.007924 |
| CREBL2 | 12 | 0.000121 | C10orf107 | 10 | 0.009278 |
| ZSWIM1 | 20 | 0.000146 | PCNA | 20 | 0.010237 |
| SP1 | 12 | 0.000228 | PALB2 | 16 | 0.012353 |
| FBXO15 | 18 | 0.000281 | DHX34 | 19 | 0.012353 |
| OR4C11 | 11 | 0.000282 | CD1E | 1 | 0.013548 |
| C17orf58 | 17 | 0.000297 | HSF5 | 17 | 0.014521 |
| SAA1 | 11 | 0.00037 | INTS7 | 1 | 0.014585 |
| SIAH1 | 16 | 0.000379 | IFNK | 9 | 0.014585 |
| COPZ1 | 12 | 0.000479 | LOC100130987 | 11 | 0.014747 |
| LIN52 | 14 | 0.000655 | ZNF420 | 19 | 0.014747 |
| C1orf116 | 1 | 0.000813 | VN1R4 | 19 | 0.016052 |
| SLC6A4 | 17 | 0.000894 | OR5D18 | 11 | 0.0181 |
| ACTR6 | 12 | 0.000942 | TMEM109 | 11 | 0.018377 |
| MED16 | 19 | 0.000948 | CDKN2A | 9 | 0.018945 |
| C22orf39 | 22 | 0.000948 | HLA-C | 6 | 0.019681 |
| FYN | 6 | 0.001036 | LTBR | 12 | 0.020236 |
| MLEC | 12 | 0.001079 | TMEM61 | 1 | 0.022593 |
| ID1 | 20 | 0.001079 | MTNR1B | 11 | 0.02273 |
| AMZ2 | 17 | 0.00129 | CD40 | 20 | 0.025506 |
| FGF14 | 13 | 0.001357 | CLIC6 | 21 | 0.029338 |
| BACH1 | 21 | 0.001549 | MRPL16 | 11 | 0.032981 |
| EXD2 | 14 | 0.00176 | FAR1 | 11 | 0.03451 |
| CBLN4 | 20 | 0.001803 | PSMD11 | 17 | 0.036848 |
| MEG8 | 14 | 0.001841 | GNAS | 20 | 0.036848 |
| NDUFS8 | 11 | 0.002252 | CADM3 | 1 | 0.038332 |
| PCBP2 | 12 | 0.002439 | TMEM49 | 17 | 0.04337 |
| SNORD17 | 20 | 0.002526 | FGF14 | 13 | 0.045241 |
| ZNF664 | 12 | 0.00283 | KRTAP | 21 | 0.045241 |
| OR11H6 | 14 | 0.003012 | OAS1 | 12 | 0.04992 |
| OR4K5 | 14 | 0.003253 |  |  |  |

**Supplementary Table 4. Network and analysis using IPA Core Analysis.** The top 93 DMRs (all p ≤ 0.05) were analysed for enrichment within the same gene interaction networks.

|  |  |
| --- | --- |
| **Top networks** | **P** |
| DNA Replication, recombination and repair, cell death and survival, gene expression | 1.00E-41 |
| Gene expression, cell death and survival, embryonic development | 1.00E-25 |
| Cell morphology, cell-to-cell signalling and interaction, tissue development | 1.00E-12 |
| Cell cycle, cellular assembly and organization, cellular compromise | 0.01 |
| Organ morphology, cancer, endocrine system disorders | 0.01 |

**Supplementary Table 5. Surrogate Variable Analysis carried out on the BATMAN array results**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **DMR region** | | **Before Surrogate Variable Analysis** | | **After Surrogate Variable Analysis** | |
|
| **Gene** | **Chr** | **Start** | **End** | **β** | **p-value** | **β** | **p-value** |
| **CDKN2A** | 9 | 21993565 | 21993664 | -27.2 | 0.0028 | -32.0 | 0.0310 |
| 21993665 | 21993764 | -22.8 | 0.0025 | -25.2 | 0.0306 |

**Supplementart Table 6. Full unclustered associations between *CDKN2A* DMR methylation and percentage and total fat mass in the SWS cohort.** Associations between % and total fat mass at birth, 4 years and 6 years for *CDKN2A*. **\* p = 0.05-0.01. \*\* p ≤ 0.01**; n=number of subjects, β=regression coefficient. Adjusted for sex, maternal age at birth and mode of delivery.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **CDKN2A** | **4 yr. DXA: Percentage fat** | | | **4 yr. DXA: total fat** | | | **6 yr. DXA: Percentage fat** | | | **6 yr. DXA: total fat** | | |
| **CpG** | **n** | **β** | **p-value** | **n** | **β** | **p-value** | **n** | **β** | **p-value** | **n** | **β** | **p-value** |
| **1** | 221 | -0.088 | **0.007\*\*** | 221 | -0.004 | **0.007\*\*** | 208 | -0.004 | **0.003\*\*** | 209 | -0.005 | **0.017\*** |
| **2** | 215 | -0.09 | **0.007\*\*** | 215 | -0.005 | **0.003\*\*** | 204 | -0.004 | **0.003\*\*** | 205 | -0.005 | **0.011\*** |
| **3** | 192 | -0.074 | 0.111 | 192 | -0.005 | **0.024\*** | 184 | -0.005 | **0.007\*\*** | 184 | -0.007 | **0.014\*** |
| **4** | 247 | -0.092 | **0.007\*\*** | 247 | -0.005 | **0.001\*\*** | 231 | -0.004 | **0.005\*\*** | 232 | -0.007 | **0.001\*\*** |
| **5** | 246 | -0.054 | 0.101 | 246 | -0.004 | **0.018\*** | 230 | -0.002 | 0.101 | 231 | -0.005 | **0.022\*** |
| **6** | 246 | -0.06 | 0.06 | 246 | -0.004 | **0.005\*\*** | 230 | -0.004 | **0.012\*** | 231 | -0.007 | **0.002\*\*** |
| **7** | 244 | -0.076 | **0.04\*** | 244 | -0.004 | **0.015\*** | 228 | -0.003 | 0.042 | 229 | -0.006 | **0.016\*** |
| **8** | 228 | -0.057 | 0.096 | 228 | -0.004 | **0.017\*** | 212 | -0.002 | 0.236 | 213 | -0.005 | **0.048\*** |
| **9** | 218 | -0.074 | 0.089 | 218 | -0.005 | **0.011\*** | 203 | -0.003 | 0.122 | 204 | -0.007 | **0.022\*** |

**Supplementary Table 7. GUSTO subject characteristics**

|  |  |  |
| --- | --- | --- |
| **Mother** | **Mean (SD) or %** | **n** |
| **Household monthly income (SGD)** |  | 373 |
| 0-1999 | 17.7 |  |
| 2000-5999 | 63.8 |  |
| ≥6000 | 18.5 |  |
| **Maternal highest education %** |  | 392 |
| ITE\_NTC | 12 |  |
| Primary | 5.4 |  |
| Secondary | 32.1 |  |
| GCE A level | 25 |  |
| University | 22.7 |  |
| Others | 2.8 |  |
| **Age at birth, years** | 30.5 (5.3) | 399 |
| **Smoker** | 3.7 | 397 |
| **BMI at 26weeks pregnancy** | 26.9 (5.0) | 394 |
| **Infant** |  |  |
| **Sex(%)** |  | 399 |
| Male | 53.1 |  |
| Female | 46.9 |  |
| Parity |  | 399 |
| Primiparous | 40.4 |  |
| Multiparous | 59.6 |  |
| Birth weight, kg | 3.1 (0.4) | 399 |
| Gestational age, weeks | 38.7 (1.2) | 399 |
| Triceps skinfold thickness at 7-days, mm | 6.4 (1.5) | 344 |
| Subscapular skinfold thickness at 7-days, mm | 5.9 (1.5) | 344 |
| Ponderal index age 18-months kg/m3 | 19 (2.0) | 299 |

**Supplementary Table 8. Associations between umbilical cord *CDKN2A* methylation and ponderal index and subscapular skinfold thickness in the GUSTO cohort at day 7 and 18 months.** Adjusted for: gender, ethnicity and cell type. n=number of subjects, b=regression coefficient.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **Ponderal index** (kg/m3) | | | **Subscapular skinfold thickness** (mm) | | |
| **cluster** | **Timepoint** | **n** | **β** | **p-value** | **n** | **β** | **p-value** |
| **1-2** | **day 7** | 242 | -1.58 | 0.718 | 242 | -0.926 | 0.747 |
| **18 month** | 215 | -6.99 | 0.061 | 205 | -2.661 | 0.349 |
| **3** | **day 7** | 217 | 0.27 | 0.960 | 217 | -9.638 | **0.004\*** |
| **18 month** | 197 | -6.61 | 0.140 | 187 | -4.112 | 0.202 |
| **4-8** | **day 7** | 282 | 2.17 | 0.363 | 282 | -2.324 | 0.125 |
| **18 month** | 252 | -2.13 | 0.262 | 236 | -0.933 | 0.509 |
| **9** | **day 7** | 204 | -3.82 | 0.387 | 204 | -4.465 | 0.085 |
| **18 month** | 183 | -10.61 | **0.005\*** | 165 | -5.822 | 0.046 |

**Supplementary Table 9. Gene expression correlates with adiposity measurements in the GUSTO cohort.** Adiposity measurements at day 7 and 18 months from infants in the GUSTO cohort were correlated to expression levels (dCt) of ANRIL linear, ANRIL unspliced, ANRIL circular, p14ARF and p16INK4a transcript levels, controlling for gender and ethnicity. n=number of subjects, b=regression coefficient.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **Ponderal index** (kg/m3) | | | **Triceps skinfold thickness** (mm) | | | **Subscapular skinfold thickness** (mm) | | |
| **Transcript** | **Timepoint** | **n** | **β** | **p-value** | **n** | **β** | **p-value** | **n** | **β** | **p-value** |
| **ANRIL (Linear)** | **day 7** | 143 | -0.03 | 0.24 | 143 | 0.19 | 0.22 | 143 | 0.12 | 0.47 |
|  | **18 month** | 148 | 0.01 | 0.56 | 144 | 0.19 | 0.31 | 140 | 0.11 | 0.42 |
| **ANRIL (Circular)** | **day 7** | 94 | 0.01 | 0.69 | 94 | 0.12 | **0.02** | 94 | 0.12 | **0.05** |
|  | **18 month** | 99 | 0.01 | 0.86 | 93 | -0.09 | 0.12 | 92 | -0.05 | 0.24 |
| **ANRIL (Unspliced)** | **day 7** | 143 | 0.01 | 0.91 | 143 | 0.51 | **0.01** | 143 | 0.63 | **0.01** |
|  | **18 month** | 148 | -0.01 | 0.76 | 144 | 0.34 | 0.11 | 140 | 0.23 | 0.15 |
| **p14ARF** | **day 7** | 143 | -0.04 | **0.04** | 143 | 0.03 | 0.81 | 143 | 0.06 | 0.68 |
|  | **18 month** | 148 | 0.01 | 0.82 | 144 | 0.15 | 0.31 | 141 | 0.18 | 0.13 |
| **p16INK4a** | **day 7** | 110 | -0.01 | 0.43 | 110 | 0.06 | 0.52 | 110 | 0.10 | 0.34 |
|  | **18 month** | 122 | 0.01 | 0.34 | 116 | 0.23 | **0.04** | 113 | 0.20 | **0.02** |

**Supplementary Table 10. Characteristics of the RAINE study participants.**

|  |  |  |
| --- | --- | --- |
| **Characteristic** | **Group/number** | **% or median (inter-quartile range)** |
| **Mother** |  |  |
| **Qualification level** | High school only | 51.60% |
|  | Trade Certificate or apprenticeship | 8.40% |
|  | Professional Registration | 8.80% |
|  | Diploma | 16.00% |
|  | University Degree | 10.00% |
|  | Other | 5.20% |
| **Smoker During Pregnancy** | No | 82.80% |
|  | Yes | 17.20% |
| **Parity** | Primiparous | 49.40% |
|  | Multiparous | 50.60% |
| **Age at birth of child (years)** | 2804 | 28 (23 to 32) |
| **Early pregnancy BMI** | 2803 | 21.3 (19.6 to 23.7) |
| **Offspring** |  |  |
| **Sex** | Male | 50.70% |
|  | Female | 49.30% |
| **Birthweight (g)** | 2858 | 3345 (2984 to 3660) |
| **Birth Length (cm)** | 2826 | 49 (47.5 to 50.5) |
| **Gestation (wks.)** | 2862 | 39.5 (38.2 to 40.7) |
| **Weight (kg) at 17 years** | 1251 | 65.4 (58.2 to 74.6) |
| **Height (cm) at 17 years** | 1251 | 172 (165 to 179) |
| **BMI (kg/m2) at 17 years** | 1251 | 22.06 (19.96 to 24.33) |
| **Abdominal skinfold thickness (mm) at 17 years** | 1155 | 19.9 (12.6 to 27.5) |
| **Triceps Skinfold Thickness (mm) at 17 years** | 1170 | 14.0(9.0 to 19.5) |

**Supplementary Table 11A. Association between cellular type and BMI in the RAINE cohort. N = 894**

|  |  |  |
| --- | --- | --- |
| **cell sub type** | **association with BMI** | |
| **Pearson Correlation** | **Sig. (2-tailed)** |
| **CD8T** | -0.098 | 0.003 |
| **CD4T** | -0.082 | 0.015 |
| **NK** | -0.079 | 0.018 |
| **B cell** | -0.079 | 0.018 |
| **Mono** | 0.043 | 0.201 |
| **Gran** | 0.160 | 0.001 |

**Supplementary Table 11B. Association between *CDKN2A* CpG methylation and cellular type in the RAINE cohort**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **CpG cluster** | **N** | **CD8T** | | **CD4T** | | **NK** | | **B cell** | | **Mono** | | **Gran** | |
| **Pearson Correlation** | **Sig. (2-tailed)** | **Pearson Correlation** | **Sig. (2-tailed)** | **Pearson Correlation** | **Sig. (2-tailed)** | **Pearson Correlation** | **Sig. (2-tailed)** | **Pearson Correlation** | **Sig. (2-tailed)** | **Pearson Correlation** | **Sig. (2-tailed)** |
| **1-2** | 1013 | 0.359 | <2.2e-16 | 0.300 | < 2.2e-16 | 0.252 | 4.44e-16 | 0.085 | 0.0104 | -0.229 | 2.41e-12 | -0.452 | < 2.2e-16 |
| **3** | 969 | 0.443 | <2.2e-16 | 0.411 | < 2.2e-16 | 0.253 | 1.33e-15 | 0.142 | 9.50e-06 | -0.319 | < 2.2e-16 | -0.562 | < 2.2e-16 |
| **4-8** | 986 | 0.618 | <2.2e-16 | 0.496 | < 2.2e-16 | 0.420 | < 2.2e-16 | 0.185 | 8.90e-09 | -0.394 | < 2.2e-16 | -0.762 | < 2.2e-16 |
| **9** | 1009 | 0.591 | <2.2e-16 | 0.621 | < 2.2e-16 | 0.364 | < 2.2e-16 | 0.243 | 8.88e-15 | -0.441 | < 2.2e-16 | -0.824 | < 2.2e-16 |

**Supplementary Table 11C. Variance Inflation Factors for *CDKN2A* CpG methylation values and cellular type in the RAINE cohort**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **CD8+ T cells** | **CD4+ T cells** | **NK cells** | **B-cell** | **Monocytes** | **granulocytes** |
| **CpG 1** | 25.2 | 61.3 | 27.6 | 14.3 | 11.4 | 110.5 |
| **CpG 2** | 25.4 | 61.1 | 28.3 | 14.5 | 11.6 | 112.1 |
| **CpG 3** | 25.6 | 61.5 | 27.9 | 14.6 | 11.6 | 112.8 |
| **CpG 4** | 25.0 | 61.2 | 30.3 | 14.7 | 11.3 | 113.7 |
| **CpG 5** | 25.2 | 61.7 | 29.9 | 14.5 | 11.4 | 115.7 |
| **CpG 6** | 24.9 | 61.3 | 29.8 | 14.5 | 11.4 | 114.8 |
| **CpG 7** | 25.3 | 62.9 | 30.3 | 15.1 | 11.8 | 116.9 |
| **CpG 8** | 24.8 | 61.4 | 30.1 | 14.7 | 11.4 | 114.1 |
| **CpG 9** | 24.7 | 61.1 | 29.6 | 14.2 | 11.3 | 112.9 |

**Supplementary Table 12.** **Characteristics of the BIOCLAIMS study participants.** Participants are grouped by % fat mass (lean/obese).Median and interquartile ranges or % are shown as appropriate.

|  |  |  |
| --- | --- | --- |
| **Measurements** | **% or median (5th,95th percentile) for BIOCLAIMS Cohort (adipose tissue) n=51** | |
|
| **Lean according to % fat mass** | **Obese according to % fat mass** |
|  |  |  |
| Age at visit | 25.60 (18.93 to 57.11) | 45.75 (22.82 to 62.3) |
| Weight (kg) | 59.80 (47.16 to 98.09) | 96.55 (66.01 to 125.73) |
| Height (M) | 1.65 (1.48 to 1.91) | 1.65 (1.53 to 1.85) |
| BMI | 22.50 (18.11 to 26.82) | 34.28 (23.63 to 40.09) |
| Waist, cm | 74.20 (65.70 to 96.09) | 105.85 (90.86 to 127.85) |
| Hip, cm | 94.40 (76.86 to 103.92) | 117.00 (97.42 to 134.02) |
| Percentage fat | 24.50 (12.24 to 31.45) | 42.65 (26.80 to 50.95) |
| Fatmass, kg | 14.60 (8.72 to 20.79) | 36.90 (22.54 to 56.90) |
| Total body water, kg | 31.10 (26.45 to 57.29) | 38.60 (30.27 to 62.45) |
| Male/Female | 19.05%/80.95% | 23.33%/76.67% |
| Lean mass, kg | 42.40 (36.16 to 78.26) | 52.70 (41.38 to 85.28) |

**Supplementary Table 13. Observed DNA methylation ranges for CpG dinucleotides quantified by Pyrosequencing.** Values are provided as percentages for pyrosequencing assays covering BATMAN-identified DMRs associated with *CDKN2A* (SWS/GUSTO)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **CDKN2A** | | | |
|  | **Median (5th, 95th percentile)** | | **Base pairs from TSS** |  |
| **CpG** | **SWS** | **GUSTO** | **ANRIL** | **Coordinates (Hg19)** |
| 1 | 71.8 (48.7, 81.3) | 81.8 (70.8, 87.1) | -1069 | chr9: 21993721 |
| 2 | 67.3 (44.8, 77.9) | 76.7 (67.1, 81.6) | -1093 | chr9: 21993697 |
| 3 | 54.8 (38.4, 62.6) | 65.8 (58.6, 70.0) | -1096 | chr9: 21993694 |
| 4 | 70.7 (50.6, 80.5) | 77.6 (59.9, 86.1) | -1136 | chr9: 21993654 |
| 5 | 58.3 (36.7, 69.6) | 67.5 (51.5, 75.7) | -1145 | chr9: 21993645 |
| 6 | 70.2 (49.6, 79.8) | 77.1 (58.7, 83.6) | -1152 | chr9: 21993638 |
| 7 | 58.2 (42.2, 68.0) | 65.9 (48.7, 73.2) | -1161 | chr9: 21993629 |
| 8 | 73.0 (55.3, 81.6) | 81.3 (62.6, 87.5) | -1187 | chr9: 21993603 |
| 9 | 60.4 (46.2, 67.6) | 76.4 (67.8, 79.8) | -1207 | chr9: 21993583 |

**Supplementary Table 14.** Primers used for pyrosequencing and real-time PCR, and in the cloning of the ANRIL promoter region.

|  |  |
| --- | --- |
| **Pyrosequencing Primer** | **Sequence** |
| CDKN2A 1-3 F | AGTAGGAAAGGTGTATTTTAAGTATATTT |
| CDKN2A 1-3 S | AGAATTATTGTTAATTATTTAAGTT |
| CDKN2A 4-9 F | TGGGGAGAATTATTGTTAATTATTTAAGTT |
| CDKN2A 4-9 S | TAGGAGAGTGGAGGA |
| CDKN2A 8-9 S | GTAGGTAGAGATTTTTTGAAATGT |
| CDKN2A 1-3 R Bio | TATCTCACCAATCCTCCACTCTCCTAAA |
| CDKN2A 4-9 R Bio | AAAAACCCATTTCCCTATTAACTACA |
| **Real-time primer** | **Sequence** |
| ANRIL unspliced F | CAGTGGCTTCCTGTTCATGC |
| ANRIL unspliced R | GGGCTTGACGTCTGATCTGT |
| ANRIL F1 | TGAAAAACACACATCAAAGGAG |
| ANRIL R1 | GATTCCACCACACCTAACAG |
| P14ARF F1 | CCCTCGTGCTGATGCTACTGAG |
| P14ARF R1 | GTGAGAGTGGCGGGGTCGGC |
| P16INK4a F1 | CGAATAGTTACGGTCGGAGGC |
| P16INK4a R1 | TCGGGTGAGAGTGGCGGGGTC |
| **Cloning Primer** | **sequence** |
| ANRIL F1 | TTGGGTACCACCTCTAACTCACAAAGAAAGC |
| ANRIL R1 | GCCAAGCTTTGGGAATGACTAAGACACAC |
| ANRIL F2 | GAGAAGCTTCCCAGGATATTCGGGACTCA |
| ANRIL R2 | TTACCATGGTGTCAGGTGACGGATGTAGC |
| **EMSA Primer** | **sequence** |
| CDK EMSA 1F | TTTCTGGAGGCGGCCTTTTTTC |
| CDK EMSA 2,3F | CCCCAGCCTCCCGGCGGGGTCACCC |
| CDK EMSA 4-7F | GAGTGGAGGACCCGTGAGATACGGGGCACGCAGGCAGCGACTTCCTGAA |
| CDK EMSA 8, 9F | CTAACAAGGATCGTAGGATCAGTTACTGCTGCGAG |
| CDK EMSA 1R | GAAAAAAGGCCGCCTCCAGAAA |
| CDK EMSA 2,3R | GGGTGACCCCGCCGGGAGGCTGGGG |
| CDK EMSA 4-7R | TTCAGGAAGTCGCTGCCTGCGTGCCCCGTATCTCACGGGTCCTCCACTC |
| CDK EMSA 8, 9R | CTCGCAGCAGTAACTGATCCTACGATCCTTGTTAG |
| ER alpha F | GATTCCTGAAGGTCAAGGTCACCAGAGCTTGGCCTG |
| ER alpha R | CAGGCCAAGCTCTGGTGACCTTGACCTTCAGGAATC |

**Supplementary Figure 1. Association between conditional abdominal circumference growth Z-score from 34 weeks gestation to birth and umbilical cord CpG3 methylation in the SWS.**



**Supplementary Figure 2. CpG Clustering.** Spearman correlation of methylation levels at CpGs 1-9 within the ANRIL promoter. Four distinct clusters are defined: 1-2, 3, 4-8 and 9. (A) correlations in the RAINE cohort. (B) correlations in the BIOCLAIMS cohort.



(B) BIOCLAIMS cohort correlations

(A) RAINE cohort correlations